AMPH amphastar.com: Enterprise Value to Sales Volume

Amphastar Pharmaceuticals Inc (AMPH) - corporate logo

Amphastar Pharmaceuticals is implementing robotic filling lines and AI-driven quality control to minimize defects in complex injectables. Stringent FDA regulations create barriers to entry for competitors, ensuring nearly total loyalty from US hospital networks. ESG environmental standards require the company to transition to safe propellants in inhalers. The company's enterprise value-to-revenue ratio demonstrates multiplier dynamics, where the value 2222.58 reflects the current magnitude.

Amphastar - AMPH EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Amphastar Pharmaceuticals, Inc. (AMPH)

- market value and analyst target forecast:
- company stock capitalization data:
Fundamental company valuation:AMPH - amphastar.com
Original product of amphastar.com

Amphastar Pharmaceuticals (AMPH) maintains strong market positions due to the technological complexity of its drugs and the transparency of its new product development. The EV/Sales metric quantifies this value by comparing the total enterprise value to sales volume, excluding the impact of debt obligations. This indicator reflects the willingness of institutional investors to pay a premium for the asset in anticipation of future margins. Rising values confirm confidence in management's competencies. By analyzing the enterprise value-to-revenue trend, one can determine optimal entry points into the asset.

Competitor analysis

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|PCRX (Pacira BioSciences) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ARS Pharmaceuticals Inc|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio